Hepatitis C virus (HCV) chronic infection affects 200 million people worldwide. HCV antiviral treatment has evolved rapidly since 2011. The use of pegylated interferon (PEG-INF) with ribavirin (RBV) has supposed high serious adverse events (SAEs) and low efficacy, especially in patients with cirrhosis. The introduction of 1st generation protease inhibitors (PIs) in genotype-1 (GT1) HCV, such as boceprevir (BOC) and telaprevir (TVR), improved the efficacy but increased the SAEs. Currently, interferon-free direct-acting antivirals (IF-DAAs) achieve great effectiveness with minimum SAEs. However, studies evaluating efficacy and safety of DAAs in cirrhotic patients are limited in real clinical practice. The aim of our study is to evaluate in HCV-cirrhotic patients the efficacy and safety of 3 treatment strategies (PEG-IFN/RBV, PEG-IFN/RBV/PIs, and IF-DAAs) in routine practice according to European guidelines from 2010 to 2015. The secondary aim is to evaluate the impact of sustained virological response on gastroesophageal varices (GOV).
Study Type
OBSERVATIONAL
Enrollment
237
sustained virological response (SVR)
undetectable HCV viral load 12 weeks after the end of antiviral treatment in each cohort of antiviral treatment
Time frame: 12 weeks after treatment completion
Number of patients with gastroesophageal varices
Number of patients with GOV before and 12-24 weeks after treatment completion in patients with or without SVR
Time frame: gastroesophageal varices (GOV) before antiviral treatment and 12-24 weeks after treatment completion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.